Mumbai, 13th August 2024: The financial statements for the first quarter of Q1 FY 25 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic.
Performance Highlights for Q1 FY25:
In the first quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 21.7 % year-over-year increase, reaching Rs. 160.63 crore compared to Rs. 132.02 crore in Q1 FY24.
EBITDA for Q1 FY25 stood at Rs. 62.54 crore, with an EBITDA Margin of 38.9%, as opposed to an EBITDA of Rs. 44.49 crore in Q1 FY24 with an EBITDA margin of 33.7%. This marks a growth of 40.6% YoY.
The Profit After Tax (PAT) for Q1 FY25 came at Rs 44.64 crore, compared to Rs 28.51 crore in Q1 FY24.
The PAT Margin stood at 27.8% in Q1 FY25, compared to 21.6% in Q1 FY24.
The company has seen good growth across different therapeutic areas in Q1FY25
European markets now contribute 51% of our business revenue up from 43% in Q4FY24 and 34% in Q1FY24.
Consolidated Financial Highlights:
|
Particulars |
Q1 FY25 |
Q1 FY24 |
YoY Growth |
|
Revenues (in Rs Cr) |
Rs. 160.63 |
Rs. 132.02 |
21.7% |
|
Gross Profit (in Rs Cr) |
Rs. 112.03 |
Rs.84.80 |
32% |
|
EBITDA (in Rs Cr) |
Rs. 62.54 |
Rs. 44.49 |
40.6% |
|
EBITDA Margin |
38.9% |
33.7% |
+524 bps |
|
PAT (in RsCr) |
Rs. 44.64 |
Rs. 28.51 |
56.6% |
|
PAT Margin |
27.8% |
21.6% |
+620 bps |
|
Quarterly EPS (in Rs) |
5.54 |
3.54 |
56.5% |
Dr Saloni Wagh, Managing Director, Supriya Lifescience Ltd, commenting on the results, said, “We are engaged in discussions with a diverse range of companies, from major pharmaceutical firms to innovative enterprises, to establish partnerships for supplying tailored products. The company achieved a record capital expenditure of Rs. 146 crore in the last financial year while also enhancing its return on equity by 210 basis points
We’re proud to unveil our new R&D facility at Lote Parshuram and anticipate the completion of our Ambernath lab by early Q2FY25. These state-of-the-art centers will drive our next phase of growth, focusing on advanced product development, CMO/CDMO opportunities, and expanding our portfolio to meet evolving market needs. Moving forward, the company aims for significant growth with improved profitability.”
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
